BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20508967)

  • 1. Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil.
    Brustoloni YM; Cunha RV; Cônsolo LZ; Oliveira AL; Dorval ME; Oshiro ET
    Infection; 2010 Aug; 38(4):261-7. PubMed ID: 20508967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
    Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
    Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
    Kuyucu N; Kara C; Bakirtaç A; Teziç T
    Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
    Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
    Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe leucopenia during treatment of visceral leishmaniasis.
    Hiçsönmez G; Jama H; Ozsoylu S
    Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
    [No Abstract]   [Full Text] [Related]  

  • 6. [Visceral leishmaniasis: retrospective study on factors associated with lethality].
    Alvarenga DG; Escalda PM; Costa AS; Monreal MT
    Rev Soc Bras Med Trop; 2010; 43(2):194-7. PubMed ID: 20464152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
    Shahian M; Alborzi A
    Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Emergent outbreak of visceral leishmaniasis in Mato Grosso do Sul State].
    Oliveira AL; Paniago AM; Dorval ME; Oshiro ET; Leal CR; Sanches M; Cunha RV; Bóia MN
    Rev Soc Bras Med Trop; 2006; 39(5):446-50. PubMed ID: 17160321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
    Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric visceral leishmaniasis in southern France.
    Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
    Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
    de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
    Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
    Gradoni L; Gramiccia M; Scalone A
    Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil.
    Alexandrino-de-Oliveira P; Santos-Oliveira JR; Dorval ME; Da-Costa Fd; Pereira GR; da Cunha RV; Paniago AM; Da-Cruz AM
    Mem Inst Oswaldo Cruz; 2010 Aug; 105(5):692-7. PubMed ID: 20835619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
    Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [N-methyl glucamine antimoniate or Glucantime].
    Rapp C; Simon F; Dordain ML
    Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
    [No Abstract]   [Full Text] [Related]  

  • 18. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
    Segura I; García-Bolao I
    Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
    Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
    Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.